Key Takeaways
- Kidney Beam raises £610,000 in seed funding to enhance its evidence-based digital health platform for kidney disease management.
- A recent clinical trial published in The Lancet Digital Health showed improved patient quality-of-life with Kidney Beam’s rehabilitation program.
- The company aims to expand its services to underserved communities and establish new partnerships in the healthcare sector.
Funding Announcement
Digital health startup Kidney Beam has successfully secured £610,000 in seed funding, bolstered by a contribution from Kidney Research UK. The company specializes in an evidence-based app that delivers virtual exercise, education, nutrition, and wellbeing programs specifically for individuals suffering from kidney disease. Named one of the NHS Innovation Accelerator companies for 2024, Kidney Beam intends to use this funding to broaden its outreach, particularly to underserved communities, improve its platform’s usability, and develop new collaborative partnerships.
Impact and Validation
Katie Bell, cofounder and CEO of Kidney Beam, expressed pride in leading the company amid prevalent funding disparities in health tech. She highlighted that the new investment underscores their commitment to advancing kidney health and the innovation’s resilience within this vital sector.
The funding follows a clinical trial published in The Lancet Digital Health in January 2024, which demonstrated a significant improvement in patient-reported quality of life for those enrolled in Kidney Beam’s 12-week digital rehabilitation program. This trial was facilitated by Kidney Research UK and conducted in collaboration with Kings College Hospital London.
Lucy Sreeves, executive director of Kidney Research UK, noted the initiative emerged from a healthcare emergency when kidney patients faced a lack of essential support. The peer-reviewed research corroborates Kidney Beam’s effectiveness in enhancing patient outcomes while offering cost savings. With the renal disease population continuing to grow, Sreeves emphasized the urgent need for investment in innovative patient care solutions like Kidney Beam, which shifts traditional medical care to a digital framework.
Addressing Challenges in Kidney Care
Kidney disease impacts one in ten adults in the UK and incurs an annual economic cost of £7 billion, as reported by Kidney Research UK. However, the availability of kidney-specific rehabilitation services is limited, partly due to a shortage of trained professionals in the field.
Cofounder and Chief Medical Officer Sharlene Greenwood remarked that this seed funding represents more than just financial support; it affirms the critical need for innovation in kidney care. She expressed gratitude towards their investors, including Kidney Research UK, the National Kidney Federation, and the Sheffield Area Kidney Association, along with contributions from the kidney community through crowdfunding.
Future Projects and Initiatives
Looking ahead, Kidney Beam plans to launch several research projects in 2025. These include studies focused on the benefits of education and exercise for individuals with polycystic kidney disease, initiatives aimed at improving digital access for those with low digital literacy, prehabilitation for transplant patients, and a mental health pilot. Additionally, the company is set to introduce “Kidney Beam Kids,” a project dedicated to children affected by kidney disease.
Kidney Beam was recognized as one of six startups reaching the finals of the Digital Health Pitchfest competition in March 2024 and was awarded the title for “Company Generating the Greatest NHS Benefit” from the DigitalHealth.London Accelerator in 2023. The company’s next strategic goal is to secure commissioning throughout the NHS, further solidifying its role in enhancing kidney health management in the UK.
The content above is a summary. For more details, see the source article.
